US Stock MarketDetailed Quotes
AMRX Amneal Pharmaceuticals
- 8.470
- +0.080+0.95%
Trading Nov 25 10:51 ET
2.62BMarket Cap-9964P/E (TTM)
8.520High8.325Low147.00KVolume8.500Open8.390Pre Close1.24MTurnover0.10%Turnover RatioLossP/E (Static)309.84MShares9.47552wk High-28.05P/B1.23BFloat Cap4.46052wk Low--Dividend TTM144.66MShs Float24.480Historical High--Div YieldTTM2.32%Amplitude1.240Historical Low8.424Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Amneal Pharmaceuticals Stock Forum
Amneal Resubmits Dhe Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, Its First Generic Injectable GLP-1 Agonist
Amneal Receives U.S. FDA Approval of New Drug Application for Pyridostigmine Bromide Extended-Release Tablets
5 MINUTES AGO, 6:00 AM EDT
VIA BUSINESSWIRE
Amneal to construct state-of-the-art manufacturing facilities and utilize existing manufacturing network to ensure supply of Metsera's portfolio of novel injectable and oral development programs, including GLP-1 and amylin receptor agonists
Agreement provides Amneal w...
Amneal and Shilpa Announce U.S. FDA Approval of Boruzu™, the First Ready-to-Use Version of Bortezomib for Subcutaneous Administration
Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials! expects launch in Q4
Amneal Pharmaceuticals, Inc. recently announced that the U.S. Food and Drug Administration (FDA) has approved CREXONT® (carbidopa and levodopa) extended-release capsules for the treatment of Parkinson’s disease (PD). This novel formulation promises to address some of the longstanding cha...
No comment yet